<em>EGFR</em>-m Adv NSCLC Key Trials: Module

CE / CME

Key Emerging Treatment Strategies for Patients With EGFR-Mutated Advanced NSCLC

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 30, 2022

Expiration: September 29, 2023

Activity

Progress
1
Course Completed

References

  1. Shah R and Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: a clash of the generations. Clin Lung Cancer. 2020;21:e216-e228.
  2. Karachaliou N, Fernandez-Bruno M, Bracht JWP, et al. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl Cancer Res. 2019;8(suppl 1):S23-S47.
  3. Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutated NSCLC. J Thorac Oncol. 2021;16:205-215.
  4. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236-1244.
  5. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study. Lung Cancer. 2021;151:20-24.
  6. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625-635.
  7. Maemondo M, Fukuhara T, Saito H, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. Presented at: 2020 Annual Meeting of the American Society of Clinical Oncology; May 29-31, 2020. Abstract 9506.
  8. Yu HA, Schoenfeld HJ, Makhnin A, et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial. JAMA Oncol. 2020;6:1048-1054.
  9. Saltos A, Baik C, Sanborn RE, et al. RAMOSE: an open-label randomized phase ii study of osimertinib with or without ramucirumab in TKI-naïve EGFR-mutated metastatic NSCLC. WCLC 2020. Abstract P76.62.
  10. Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutated lung cancer. Clin Cancer Res. 2020;26:2654-2663.
  11. Sequist LV, Han J, Ahn M, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21:373-386.
  12. Cho BC, Piotrowska Z, Le X, et al. ORCHARD: a biomarker-directed phase 2 platform study in pts with advanced EGFRm NSCLC progressing on first-line osimertinib. WCLC 2020. Abstract P76.27.
  13. Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer. 2021;22:601-606.
  14. Yu HA, Ambrose H, Baik C, et al. ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. ESMO 2021. Abstract 1239P.
  15. Ahn M, de Marinis F, Bonanno L, et al. MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib + osimertinib in EGFRm NSCLC post-osimertinib. WCLC 2022. Abstract EP-08.02-140.
  16. Lu S, Xu W, Telaranta-Keerie A, et al. SAFFRON: Ph3 savolitinib + osimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression/amplification post-osimertinib. WCLC 2022. Abstract EP-08.02-138.
  17. Dokala A, Thakur SS. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene. 2017;36:2337-2344.
  18. Lyu H, Han A, Polsdofer E, et al. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 2018;8:503-510.
  19. HER2-/HER3-targeting antibody–drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers (Basel). 2021;13:1047.
  20. Scharpenseel H, Hanssen A, Loges S, et al. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019;9:7406.
  21. Hashimoto Y, Koyama K, Kamai Y, et al. A novel HER3-targeting antibody–drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin Cancer Res. 2019;25:7151-7161.
  22. Jänne PA, Baik C, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74-89.
  23. Jänne PA, Baik C, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9007.
  24. Shu CA, Goto K, Ohe Y, et al. Amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: updated results from CHRYSALIS-2. Presented at: 2022 ASCO annual meeting; June 3-7, 2022. Abstract 9006.
  25. Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Presented at: 2021 ASCO annual meeting; June 4-8, 2021. Abstract 9006.
  26. Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76:3942-3953.
  27. Yun J, Lee S, Kim S, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10:1194-1209.
  28. Amivantamab-vmjw prescribing information. Raritan, NJ: Janssen Biotech, Inc.; 2021.
  29. Ahn M, Han J, Lee K, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681-1690.
  30. Kim S, Ahn M, Han J, et al. Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: data from a phase I/II study. Presented at: 2022 ASCO annual meeting; June 3-7, 2022. Abstract 9571.